228 related articles for article (PubMed ID: 17726452)
21. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
Drabek D; Guy J; Craig R; Grosveld F
Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711
[TBL] [Abstract][Full Text] [Related]
22. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
Chung-Faye G; Palmer D; Anderson D; Clark J; Downes M; Baddeley J; Hussain S; Murray PI; Searle P; Seymour L; Harris PA; Ferry D; Kerr DJ
Clin Cancer Res; 2001 Sep; 7(9):2662-8. PubMed ID: 11555577
[TBL] [Abstract][Full Text] [Related]
23. High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue.
Lipinski KS; Djeha AH; Ismail T; Mountain A; Young LS; Wrighton CJ
Mol Ther; 2001 Oct; 4(4):365-71. PubMed ID: 11592840
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Palmer DH; Milner AE; Kerr DJ; Young LS
Br J Cancer; 2003 Sep; 89(5):944-50. PubMed ID: 12942130
[TBL] [Abstract][Full Text] [Related]
25. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
[TBL] [Abstract][Full Text] [Related]
26. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
Bailey SM; Knox RJ; Hobbs SM; Jenkins TC; Mauger AB; Melton RG; Burke PJ; Connors TA; Hart IR
Gene Ther; 1996 Dec; 3(12):1143-50. PubMed ID: 8986441
[TBL] [Abstract][Full Text] [Related]
27. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
28. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
30. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene.
Searle PF; Weedon SJ; McNeish IA; Gilligan MG; Ford MJ; Friedlos F; Springer CJ; Young LS; Kerr DJ
Adv Exp Med Biol; 1998; 451():107-13. PubMed ID: 10026858
[No Abstract] [Full Text] [Related]
31. Adenoviral interleukin-3 gene-radiation therapy for prostate cancer in mouse model.
Oh YT; Chen DW; Dougherty GJ; McBride WH
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):579-83. PubMed ID: 15145179
[TBL] [Abstract][Full Text] [Related]
32. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
Palmer DH; Chen MJ; Searle PF; Kerr DJ; Young LS
Gene Ther; 2005 Aug; 12(15):1187-97. PubMed ID: 15800660
[TBL] [Abstract][Full Text] [Related]
34. Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer.
Onion D; Patel P; Pineda RG; James N; Mautner V
Hum Gene Ther; 2009 Nov; 20(11):1249-58. PubMed ID: 19619056
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
[TBL] [Abstract][Full Text] [Related]
36. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
Hsieh CL; Chung LW
Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
[TBL] [Abstract][Full Text] [Related]
37. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
Benouchan M; Do Nascimento F; Perret GY; Colombo BM
Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
[TBL] [Abstract][Full Text] [Related]
38. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
39. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
40. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
White CL; Menghistu T; Twigger KR; Searle PF; Bhide SA; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Mar; 15(6):424-33. PubMed ID: 18079753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
